Cystadrops in Pediatric Cystinosis Patients From Six Months to Less Than Two Years Old (SCOB2)
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Cystadrops® is currently indicated in adults and children from 2 years of age diagnosed with
cystinosis with corneal crystal accumulation observed.
However administration of Cystadrops® in patients below 2 years old could be of value for
these patients and prevent the crystal deposit. It is the reason why as part of the
Cystadrops® pediatric investigational plan (PIP), RECORDATI Rare Diseases committed to
conduct a clinical study to assess Cystadrops® safety and efficacy in the pediatric
population from 6 months to less than 2 years old.